BMS

Bristol-Myers Squibb is a biopharmaceutical firm that discovers, develops and delivers medicines for patients prevail over serious diseases. Read more

67,138 Followers on Owler
67,138 Followers on Owler
67,138 Followers on Owler
67,138 Followers on Owler

BMS

Bristol-Myers Squibb is a biopharmaceutical firm that discovers, develops and delivers medicines for patients prevail over serious diseases. Read more

Giovanni Caforio's photo - Chairman & CEO of BMS

Chairman & CEO

Giovanni Caforio

CEO Approval Rating

62/100

Founded:

1858

Status:

PublicIndependent CompanyNYSEBMY

BMS TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Merck has been one of BMS's top competitors. Merck was founded in 1891, and is headquartered in Kenilworth, New Jersey. Merck competes in the Pharmaceuticals industry. Merck generates $5.5B more revenue vs. BMS.

Roche is a top competitor of BMS. Roche is a Public company that was founded in Basel, Basel-Country in 1896. Like BMS, Roche also competes in the Pharmaceuticals industry. Roche has 76,700 more employees vs. BMS.

Gilead is perceived as one of BMS's biggest rivals. Gilead was founded in 1987, and its headquarters is in Foster City, California. Like BMS, Gilead also operates in the Pharmaceuticals field. Gilead has 9,700 fewer employees than BMS.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Pfizer a competitor of BMS?

BMS Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$42.5B

BMS's revenue is the ranked 7th among it's top 10 competitors. The top 10 competitors average 31.8B. Over the last four quarters, BMS's revenue has grown by 9.3%. Specifically, in Q1 2021's revenue was $11.1B; in Q4 2020, it was $11.1B; in Q3 2020, it was $10.5B; in Q2 2020, BMS's revenue was $10.1B.

BMS Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Myokardia, Inc.

Oct 2020

Source »
$13.1B
MyoKardia is a biopharmaceutical company that develops and commercializes therapies for the treatment of cardiovascular diseases.
Forbius

Aug 2020

Source »
undisclosed
Forbius designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases.
Celgene Corporation

Jan 2019

Source »
$74B
Celgene develops and commercializes novel therapies for the treatment of cancer and inflammatory diseases.
IFM Therapeutics, LLC

Aug 2017

Source »
$300M
IFM is a biopharmaceutical company that develops and commercializes small molecule therapies for the treatment of cancer and inflammatory disorders.
Cormorant Pharmaceuticals

Jul 2016

Source »
$500M
Cormorant Pharmaceuticals engages in the research and development of therapeutics for the treatment of cancer and rare diseases.

These are all the companies that BMS has acquired. BMS has acquired 22 companies and its latest acquisition was Myokardia, Inc. in Oct 2020. MyoKardia is a biopharmaceutical company that develops and commercializes therapies for the treatment of cardiovascular diseases.

BMS Funding History

No recent funding data found related to BMS

BMS Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

Exscientia is an England-based AI platform that provides drug discovery and development solutions for biotechnology and pharmaceutical companies.
$225M
Apr 26, 2021
Series D
-
Aktis is a Massachusetts-based biotechnology firm that develops and commercializes radiopharmaceuticals for the treatment of cancer.
$72M
Mar 17, 2021
Series A
-
Presage Biosciences is a biotechnology company that researches and develops novel therepatics for the treatment of cancer.
$7M
Mar 02, 2021
Venture Round
-
Exscientia is an England-based AI platform that provides drug discovery and development solutions for biotechnology and pharmaceutical companies.
$40M
Mar 02, 2021
Series C
-
Orna Therapeutics is a biotechnology company that develops engineered circular RNA therapeutics to treat cancer, autoimmune and genetic disorders.
$80M
Feb 23, 2021
Series A
-

These are all the companies that BMS has invested in. BMS has invested 22 companies and its latest investment was Myokardia, Inc. in Oct 2020. MyoKardia is a biopharmaceutical company that develops and commercializes therapies for the treatment of cardiovascular diseases.

BMS News

May 3, 2021MarketScreener

Presents New Clinical and Real-World Data on Mavacamten and Obstructive Hypertrophic Cardiomyopathy at Upcoming American College of Cardiology's 70th Annual Scientific Session

(marketscreener.com) New analysis of EXPLORER-HCM trial assessing impact of mavacamten on patient's h... See more »
April 30, 2021Global Legal Chronicle

Agios's $345 Million Repurchase Agreement With Bristol-Myers Squibb Company

Wachtell, Lipton, Rosen & Katz advised Agios Pharmaceuticals on the deal. Agios Pharmaceuticals, Inc.... See more »
April 30, 2021Pharamceutical Technology

Bristol Myers Squibb revenues increase in Q1 2021

Bristol Myers Squibb has reported revenues of $11.1bn for the first quarter of this year, which repre... See more »
April 30, 2021Drug Discovery and Development

Exscientia raises $225M for drug discovery AI

AI-powered drug discovery company Exscientia announced that it completed a $225 Series D funding roun... See more »
April 30, 2021Endpoints News

Bristol Myers' Opdivo scores priority review in common bladder cancer, marking latest win in PD-1 battle with Keytruda

Two months after Bristol Myers Squibb announced Opdivo nearly doubled the average length of time pati... See more »
April 29, 2021Pharmafile

Bristol Myers Squibb psoriasis drug shows positive Phase III results

Bristol Myers Squibb's investigational deucravacitinib drug, for the treatment of moderate-to-severe ... See more »
April 29, 2021PharmaLive

Bristol Myers first-quarter earnings miss expectations as cancer drugs underperform

Bristol Myers Squibb Co. reported lower-than-expected first-quarter profit on April 29 as sales of th... See more »

BMS Press Releases

March 30, 2021Business Wire

Bristol Myers Squibb to Host Virtual Investor Event to Discuss AAD VMX Highlights

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb to Host Virtual Investor Event to Discuss AA... See more »
March 29, 2021Business Wire

European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Opdivo--European Medicines Agency Validates BMS's Applicat... See more »
January 12, 2021Cision Canada

Health Canada Approves ONUREG (azacitidine tablets), First Maintenance Therapy for Patients in Remission from Acute Myeloid Leukemia

/CNW/ - Bristol Myers Squibb Canada (BMS) announced today that Health Canada has approved ONUREG® (az... See more »
January 4, 2021Business Wire

Bristol Myers Squibb to Present at J.P. Morgan's 39th Annual Virtual Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb to Present at J.P. Morgan's 39th Annual Virtual Healt... See more »
December 23, 2020Business Wire

Bristol Myers Squibb Announces Update on Phase 3 CheckMate -548 Trial Evaluating Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--BMS Announces Update on Phase 3 CheckMate -548 Trial ... See more »
December 10, 2020Business Wire

Bristol Myers Squibb Announces Dividend Increase

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend Increase... See more »

BMS Videos

Social Media

BMS Headquarters

430 E 29th Street 14th Floor

New York, New York10016

1-800-332-2056

Driving Directions »

Trending Companies

BMS Summary

ABOUT

Overview

Bristol-Myers Squibb is a biopharmaceutical firm that discovers, develops and delivers medicines for patients prevail over serious diseases. BMS was founded in 1858. BMS's headquarters is located in New York, New York, USA 10016. BMS's Chairman & CEO...

CEO

BMS's Chairman & CEO, Giovanni Caforio, currently has an approval rating of 62%. BMS's primary competitors are Merck, Roche & Gilead.

Website

bms.com

Frequently Asked Questions about BMS

  1. When was BMS founded?

    BMS was founded in 1858
  2. Who is BMS's CEO?

    BMS's CEO is Giovanni Caforio
  3. How much revenue does BMS generate?

    BMS generates $42.5B in revenue
  4. How much funding does BMS have?

    BMS has historically raised $0 in funding
  5. Where is BMS's headquarters?

    BMS's headquarters is in New York New York, USA
  1. How many employees does BMS have?

    BMS has 23,300 employees
  2. What sector does BMS operate in?

    BMS is in Pharmaceuticals, Biotechnology
  3. Who are BMS's competitors?

    BMS's top competitors are Merck, Roche, Gilead
  4. Who has BMS invested in?

    BMS's has invested in companies such as Exscientia, Aktis Oncology, Presage Biosciences